The therapeutic potential of lactoferrin

Bibliography

• WEINBERG ED: Human lactoferrin: a novel therapeutic with broad spectrum potential. ./. Pharm. Pharmaca (2001) 53:1303–1310.
   PubMed Web of Science ®Google Scholar
• WEINBERG ED: Iron, infection and sudden infant death. Med. Hypoth. (2001) 56:731–734.
   PubMed Web of Science ®Google Scholar
• GUTTEBERG TJ, HANSBERG H, JORGENSEN T: The latency of serum acute phase proteins in meningococcal septicemia with special emphasis on lactoferrin. Clin. Chim. Acta (1984) 136:173–178.
   PubMed Web of Science ®Google Scholar
• CHEWONARIN T, KUWAHARA T, ARIMOCHI H et al.: Expression of human lactoferrin in Bacteroides uniformis and its effect on azoxymethane-induced aberrant crypt focus formation in the rat colon. Anaerobe (2001) 7:247–253.
   Web of Science ®Google Scholar
• WARD PP, PIDDINGTON DS, CUNNINGHAM GA, ZHOU X, WYATT RD, CONNEELY OM: A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology (1995) 13:498–503.
   PubMed Web of Science ®Google Scholar
• •Development of a frequently used rhLf.
   Google Scholar
• LIANG Q, RICHARDSON T: Expression and characterization of human lactoferrin in yeast Saccharomyces cerevisiae. .1. Agric. Food Chem. (1993) 41:1800–1807.
   Web of Science ®Google Scholar
• ARAKAWA T, CHONG DKX, SLATTERY CW, LANGRIDGE WHR: Improvements in human health through production of human milk proteins in transgenic food plants. In: Chemicals via Higher Plant Bioengineering. S Shahidi (Ed.), Kluwer Academic/Plenum Publishers, New York (1999):149–160.
   Google Scholar
• MITRA A, ZHANG Z: Expression of human lactoferrin cDNA in tobacco cells produces antibacterial protein(s). Plant Physia (1994) 106:977–981.
   PubMed Web of Science ®Google Scholar
• NANDI S, SUSUKI YA, HUANG J et al: Expression of human lactoferrin in transgenic rice grains for the application in infant formula. Plant Sci. (2002) 163:713–722.
   Web of Science ®Google Scholar
• •A novel method for incorporation of Lf in food.
   Google Scholar
• HUMPHREY BD, HUANG N, KLASING RC: Rice expressing lactoferrin and lysozyme has antibiotic-like properties when fed to chicks.' Nutr. (2002) 132:1214–1218.
   PubMed Web of Science ®Google Scholar
• •May replace use of antibiotics in animal feed.
   Google Scholar
• STOWELL KM, RADO TA, FUNK WD, TWEEDIE JW: Expression of cloned human lactoferrin in baby-hamster kidney cells. Biochem. (1991) 276:349–355.
   Google Scholar
• VAN BERKEL PHC, WELLING MM, GEERTS M et al.: Large scale production of recombinant human lactoferrin in milk of transgenic cows. Nat. Biotechnol (2002) 20:484–487.
   PubMed Web of Science ®Google Scholar
• •Development of an efficient source of rhLf.
   Google Scholar
• PARAMASIVAN M, SARAVANAN K, UMA K, SHAMA S, SINGH TP, SRINIVASAN A: Expression, purification, and characterization of equine lactoferrin in Pichia pastoris. Prot. Expression Purific. (2002) 26:28–34.
   PubMed Web of Science ®Google Scholar
• WANG OH, YANG TS, LIN SM, TSAI MS, WU SC, MAO SJT: Expression, characterization, and purification of recombinant porcine lactoferrin in Pichia pastoris. Prot. Expression Purific. (2002) 25:41–49.
   PubMed Web of Science ®Google Scholar
• ELLISON RT III, GIEHL TJ: Killing ofGram-negative bacteria by lactoferrin and lysozyme. Clin. Invest. (1991) 88:1080–1091.
   Google Scholar
• LEITCH EC, WILLCOX MDP: Synergic antistaphylococcal properties of lactoferrin and lysozyme. .1. Med. Microbia (1998) 47:837–842.
   PubMed Web of Science ®Google Scholar
• WEINBERG ED: The mutual effects of antimicrobial compounds and metallic cations. Bacteria Rev (1957) 21:46–68.
   PubMedGoogle Scholar
• FOWLER CE, SOOTHILL JS, OAKES L: MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when human lactoferrin is present. Antimicrob. Chemother. (1997) 40:877–879.
   Web of Science ®Google Scholar
• ALKAWASH M, HEAD M, ALSHAMI I, SOOTHILL JS: The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains. Antimicrob. Chemother. (1999) 44:385–387.
   Web of Science ®Google Scholar
• LEITCH EC, WILLCOX MDP: Lactoferrin-induced reduction of vancomycin resistance in enterococci. Internat. .1 Antimicrob. Agents (2001) 18:399–402.
   Google Scholar
• AGUILA A, HERRERA AG, MORRISON D et al.: Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immuna Med. Microbia (2001) 31:145–152.
   PubMed Web of Science ®Google Scholar
• SINGH PK, PARSEK MR, GREENBERG EP, WELSH MJ: A component of innate immunity prevents bacterial biofilm development. Nature (2002) 6888:552–555.
   Web of Science ®Google Scholar
• •An important use of Lf.
   Google Scholar
• STENFORS LE, BYE HM, VORLAND LH: Remarkable attachment of lactoferrin to Streptococcus pyogenes during acute pharyngo-tonsillitis. Acta Otolaryngol (2001) 121:637–642.
   PubMed Web of Science ®Google Scholar
• AJELLO M, GRECO R, GIANSANTI F, MASSUCCI MT, ANTONINI G, VALENTI P: Anti-invasive activity of bovine lactoferrin towards group A streptococci. Biochem. Cell Biol. (2002) 80:119–124.
   PubMed Web of Science ®Google Scholar
• DE OLIVEIRA IR, DE ARAUJO AN, BAO SN, GIUGLIIANO LG: Binding of lactoferrin and free secretory component to enterotwdgenic Escherichia coil. FEMS Microbia Lett. (2001) 203:29–33.
   PubMed Web of Science ®Google Scholar
• GOMEZ HF, OCHOA TJ, CARLIN LG,CLEARY TG: Human lactoferrin impairs virulence of Shigella flexneri. I Infect. Dis. (2003) 187:87–95.
   PubMed Web of Science ®Google Scholar
• HENDRIXSON DR, QIU J, SHEWRY SC et al: Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol Microbia (2003) 47:607–617.
   PubMed Web of Science ®Google Scholar
• ANTONINI G, CATANIA MR, GRECO R et al.: Anti-invasive activity of bovine lactoferrin against Listeria monocytogenes. Food Protect. (1997) 60:267–271.
   Web of Science ®Google Scholar
• HIRANO Y, TAMURA M, HAYASHI K: Inhibitory effect of lactoferrin on the adhesion of Prevotella nigrescens ATCC 25261 to hydroxyapatite. Oral. Sci. (2000) 42:125–131.
   PubMedGoogle Scholar
• ALMSTAHL A, WIKSTROM M, BEYDOUIN F: Lactoferrin amylase and mucin MUC5B and their relation to the oral microflora in hyposalivation of different origins. Oral Microbia Immuna (2001) 16:345–352.
   PubMedGoogle Scholar
• FINE DH, FURGANG D, BEYDOUIN F:Lactoferrin iron levels are reduced in saliva of patients with localized aggressive periodonitis. Periodontol (2002) 73:624–630.
   PubMed Web of Science ®Google Scholar
• KALMAR JR, ARNOLD RR: Killing ofActinobacillus actinomycetemcomitans by human lactoferrin. Infect. Immun. (1988) 56:2552–2557.
   PubMed Web of Science ®Google Scholar
• FINE DH, FURGANG D: Lactoferrin ironlevels affect attachment of Actinobacillus actinomycetemcomitans to buccal epithelial cells. Periodontol (2002) 73:616–623.
   PubMed Web of Science ®Google Scholar
• EDDE L, HIPOLITO RB, HWANG FFY, HEADON DR, SHALWITZ RA, SHERMAN MP: Lactoferrin protects neonatal rats from gut-related systemic infection. Am. Physiol Castrointest. Liver Physiol (2001) 281:G1140–G1150.
   PubMed Web of Science ®Google Scholar
• GOMEZ HF, OCHOA TJ, HERRERA-INSUA I, CARLIN LG, CLEARY TG: Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infect. Immun. (2002) 70:7050–7053.
   PubMed Web of Science ®Google Scholar
• DIAL EJ, HALL LR, SERNA H, ROMERO JJ, FOX JG, LICHTENBERGER LM: Antibiotic properties of bovine lactoferrin on Helicobacter py/ori. Dig. Dis. Sci. (1998) 43:2750–2756.
   PubMed Web of Science ®Google Scholar
• DIAL EJ, ROMERO JJ, HEADON DR,LICHTENBERGER LM: Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. Pharm. Pharmacol (2000) 52:1541–1546.
   PubMed Web of Science ®Google Scholar
• BHIMANI RS, VENDROV Y, FURMANSKI P: Influence of lactoferrin feeding and injection against systemic staphylococcal infections on mice.' Appl. Microbiol (1999) 86:135–144.
   Google Scholar
• HAVERSEN LA, ENGBERG I, BALTZER L, DOLPHIN G, HANSON LA, MATTSBY-BALTZER I: Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coil urinary tract infection in mice. Infect. Immun. (2000) 68:5816–5823.
   PubMed Web of Science ®Google Scholar
• NAIDU AS: Activated lactoferrin - a new approach to meat safety. Food Technol (2002) 56:40–45.
   Web of Science ®Google Scholar
• •An important non-medicinal use of Lf.
   Google Scholar
• ANDERSSON Y, LINDQUIST S, LAGERQVIST C, HERNELL 0: Lactoferrin is responsible for the fungistatic effect of human milk. Early Hum. Dev. (2000) 59:95–105.
   PubMed Web of Science ®Google Scholar
• CIRONI 0, GIACOMETTI A, BARCHIESI F, SCALISE G: Inhibition of growth of Pneumocystis carinii by lactoferrin alone and in combination with pyrimethamine, clarithromycin and minocycline.f Antimicrob. Chemother: (2000) 46:577–582.
   Google Scholar
• KUIPERS ME, DE VRIES HG, EIKELBOOM MC, MEIJER DCF, SWART PJ: Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother: (1999) 43:2635–2641.
   PubMed Web of Science ®Google Scholar
• VAN DER STRATE BWA, HARMSEN MC, THE TH et al.: Plasma lactoferrin levels are decreased in end-stage AIDS patients. Viral kimunol. (1999) 12:197–203.
   Google Scholar
• KUIPERS ME, BELJAARS L, VAN BEEK N et al.: Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida. Acta Pathol Microbiol Immunol Scand. (2000) 110:290–298.
   Google Scholar
• MASCI JR: Complete response of severe,refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. AIDS (2000) 14:2403–2404.
   PubMed Web of Science ®Google Scholar
• LIMA ME KIERSZENBAUM F: Lactoferrin effects on phagocytic cell function. II. The presence of iron is required for the lactoferrin molecule to stimulate intracellular killing by macrophages but not to enhance the uptake of particles and microorganisms. .1. Immunol (1987) 139:1647–1651.
   Google Scholar
• FRITSCH G, SAWATZKI G, TREUMER J, JUMO A, SPIRA DT: Plasmodium fakiparum: inhibition M vitro with lactoferrin, desferrithiocin, and desferricrocin. Exp. Parasitol (1987) 63:1–9.
   PubMed Web of Science ®Google Scholar
• MARCHETTI M, PISANI S, ANTONINI G, VALENTI P, SEGANTI L, ORSI N: Metal complexes of bovine lactoferrin inhibit M vitro replication of herpes simplex virus Type 1 and 2. BioMetals (1998) 11:89–94.
   PubMed Web of Science ®Google Scholar
• ARNOLD D, DI BIASE AM, MARCHETTI M et al.: Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res. (2002) 53:153–158.
   PubMed Web of Science ®Google Scholar
• HARMSEN MC, SWART PJ, DE BETHUNE M-P et al: Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication M vitro.Infect. Dis. (1995) 172:380–388.
   Google Scholar
• HARA K, IKEDA M, SAITO S et al: Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res. (2002) 24:228–235.
   PubMed Web of Science ®Google Scholar
• IKEDA M, SUGIYAMA K, TANAKA T et al.: Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun. (1998) 245:549–553.
   PubMed Web of Science ®Google Scholar
• LIN T-Y, CHU C, CHIU C-H: Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. Infect. Dis. (2002) 186:1161–1164.
   Google Scholar
• MURPHY ME, KARIWA H, MIZUTANI T, YOSHIMATSU K, ARIKAWA J, TAKASHIMA I: ha vitro antiviral activity of lactoferrin and ribivarin upon hantavirus. Arch. Virol (2000) 145:1571–1582.
   PubMed Web of Science ®Google Scholar
• TANAKA K, IKEDA M, NOZAKI A et al:Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. fpn. .1. Cancer Res. (1999) 90:367–371.
   PubMed Web of Science ®Google Scholar
• OKADA S, TANAKA K, SATO T et al: Dose-response trial of lactoferrin in patients with chronic hepatitis C. fpn. I Cancer Res. (2002) 93:1063–1069.
   PubMed Web of Science ®Google Scholar
• DAMIENS E, YAZIDI IE, MAZURIER J, DUTHILLE I, SPIK G, BOILLY-MARERY: Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells.' Cell. Biochem. (1999) 74:486–498.
   PubMed Web of Science ®Google Scholar
• BEZAULT JA, BHIMINI R, WIPROVNICK J, FURMANSKI P: Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. (1994) 54:2310–2312.
   PubMed Web of Science ®Google Scholar
• TSUDA H, SEKINE K, FUJITA K, IIGO M: Cancer prevention by bovine lactoferrin and underlying mechanisms - a review of experimental and clinical studies. Biochem. Cell Biol. (2002) 80:131–136.
   PubMed Web of Science ®Google Scholar
• USHIDA Y, SEKINE K, KUHARA T et al.: Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. fpn..1. Cancer Res. (1999) 90:262–267.
   Google Scholar
• NORRBY K, BALTZER IM, INNOCENTI M, TUNEBERG S: Orally administered bovine lactoferrin systemically inhibits VEGF (165)-mediated angiogenesis in the rat. [nt.j Cancer (2001) 91:236–240.
   PubMed Web of Science ®Google Scholar
• GUILLEN C, MCINNES TB, VAUGHN DM, SPEEKENBRINK ABJ, BROCK JH: The effects of local administration of lactoferrin on inflammation in murine autoimmune and infectious arthritis. Arthritis Rheum. (2000) 43:2073–2080.
   PubMed Web of Science ®Google Scholar
• TRIF M, GUILLEN C, VAUGHN DM et al.: Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp. Biol. Med. (2001) 226:559–564.
   PubMed Web of Science ®Google Scholar
• •Enhancement of therapeutic potential of Lf.
   Google Scholar
• BRANDENBURG K, JURGENS G, MULLER M, FUKUOKA 0, KOCH MHJ: Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol. Chem. (2001) 382:1215–1225.
   PubMed Web of Science ®Google Scholar
• LEE WJ, FARMER JL, HILTY M, KIM YB: The protective effect of lactoferrin feeding against endotwdn lethal shock in germfree piglets. Infect. Immun. (1998) 66:1421–1426.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI M, MATASURA M, KOBAYASHI K, SASAKI H, YAJIMA T, KUWATA T: Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin. Diagn. Lab. Immuna (2001) 8:1234–1239.
   PubMedGoogle Scholar
• SEIFERT J, MOLKEWEHRUM M, OESSER S, NEBERMANN L, SCHULZ C: Endotoxin inactivation by enterally applied colostrums of different composition. Ea Surg. Res. (2002) 34:68–72.
   PubMed Web of Science ®Google Scholar
• BAVEYE S, ELASS E, FERNIG DG, BLANQUART C, MAZURIER J, LEGRAND D: Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesin molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect. Inman. (2000) 68:6519–6525.
   PubMed Web of Science ®Google Scholar
• TOGAWA JI, NAGASE H, TANAKA K et al.: Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J. Castroentera Hepata (2002) 17:1291–1298.
   PubMed Web of Science ®Google Scholar
• KRUZEL ML, HARARI Y, MAILMAN D, ACTOR JK, ZIMECKI M: Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immuna (2002) 130:25–31.
   PubMed Web of Science ®Google Scholar
• SATO R, INANAMI 0, TANAKA Y, TAKASE M, NAITO Y: Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FW)- positive and FIV-negative cats. Am. .1. Vet. Res. (1996) 57:1443–1446.
   Google Scholar
• GRIFFITHS CEM, CUMBERTATCH M, TUCKER SC et al.: Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. Br. Dermata (2001) 144:715–725.
   PubMed Web of Science ®Google Scholar
• GUILLEN C, MCINNES TB, VAUGHN DM et al.: Enhanced Thl response to Staphylococcus aureusinfection in human lactoferrin-transgenic mice. Immuna (2002) 168:3950–3957.
   PubMed Web of Science ®Google Scholar
• RAGHUVEER TS, MCGUIRE EM, MARTIN SM et al.: Lactoferrin in the preterm infants' diet attenuates iron-induced oxidation products. Pediati: Res. (2002) 52:964–972.
   PubMed Web of Science ®Google Scholar
• STEIJNS JM, VAN HOOIJDONK ACM: Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br. Nutr. (2000) 84\(Suppl. 1):S11–517.
   Google Scholar
• TROOST FJ, STEIJNS JM, SARIS WHM, BRUMMER R-JM: Gastric digestion of bovine lactoferrin in vivo in adults. Nutr. (2001) 131:2101–2104.
   Web of Science ®Google Scholar
• KUWATA H, YAMAUCHI K, TERAGUCHI S et al.: Functional fragments of ingested lactoferin are resistant to proteolytic degradation in the gastrointestinal tracts of adult rats. J. Nutr. (2001) 131:2121–2127.
   PubMed Web of Science ®Google Scholar
• TROOST FJ, SARIS WHM, BRUMMER R-JM: Orally ingested human lactoferrin is digested and secreted in the upper gastrointestinal tract in vivo in women with ileostomies. Nutr. (2002) 132:2597–2600.
   Web of Science ®Google Scholar
• •Specific knowledge of fate of oral Lf.
   Google Scholar
• NIBBERING PH, RAVENSBERGEN E, WELLING MM et al.: Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun. (2001) 69:1469–1476.
   PubMed Web of Science ®Google Scholar
• BELLAMY W, TAKASE H, WAKABAYASHI H, KAWASE K, TOMITA M: Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. Appl Bacteria (1992) 73:472–479.
   PubMedGoogle Scholar
• JONES EM, SMART A, BLOOMBERG G, BURGESS L, MILLAR MR: Lactoferricin, a new antimicrobial peptide. Appl Bacteria (1994) 77:208–214.
   PubMedGoogle Scholar
• ULVATNE H, HAUKLAND HH, SAMUELSON 0, KRAMER M, VORLAND LH: Proteases in Esherichia coil and Staphylpcoccus aureus confer reduced susceptibility to lactoferricin B. Antimicrob. Chemother. (2002) 50:461–467.
   Web of Science ®Google Scholar
• ULVATNE H, VORLAND LH: Bactericidal kinetics of 3 lactoferricins against Staphylococcus aureus and Escherichia coil. Scand. .1. Infect. Dis. (2001) 33:507–511.
   PubMed Web of Science ®Google Scholar
• STROM MB, REKDAL 0, STENSENVV, SVENDSEN JS: Increased antibacterial activity of 15-residue murine lactoferrin derivatives. J. Peptide Res. (2001) 57:127–139.
   PubMedGoogle Scholar
• CHAPPLE DS, MASON DJ, JOANNU CL, ODELL EW, GANT V, EVANS RW: Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coil serotype 0111. Infect. Inman. (1998) 66:2434–2440.
   PubMed Web of Science ®Google Scholar
• TERAGUCHI S, SHIN K, OZAWA K et al.: Bacteriostatic effect of orally administered bovine lactoferrin on proliferation of Clostridium species in the gut of mice fed bovine milk. Appl. Environ. Microbia (1995) 61:501–506.
   PubMed Web of Science ®Google Scholar
• WAKABAYASHI H, ABE S, TERAGUCHI S, HAYASAWA H, YAMAGUCHI H: Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemother. (1998) 42:1587–1591.
   PubMed Web of Science ®Google Scholar
• LUPETTI A, PAULUSMA-ANNEMA A, WELLANG MM et al.: Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother. (2003) 47:262–267.
   PubMed Web of Science ®Google Scholar
• TANIDA T, RAO F, HAMADA T, UETA E, OSAKI T: Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect. Inman. (2001) 69:3883–3890.
   PubMed Web of Science ®Google Scholar
• SUPERTI F, SICILIANO R, REGA B, GIANSANTI F, VALENTI P, ANTONINI G: Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim. Biophys. Acta (2001) 1528:107–115.
   PubMed Web of Science ®Google Scholar
• ANDERSEN JH, OSBAKK SA, VORLAND LH, TRAAVIK T, GUTTEBERG TJ: Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. (2001) 51:141–149.
   PubMed Web of Science ®Google Scholar
• BERKHOUT B, VAN WAMEL JLB, BELJAARS L, MEIJER DKF, VISSER KS, FLORIS R: Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res. (2002) 55:341–355.
   PubMed Web of Science ®Google Scholar
• IKEDA M, NOZAKI A, SUGIYAMA K et al.: Characterization of antiviral activity of lactoferrin against hepatitis C virus in human cultured cells. Virus Res. (2000) 66:51–63.
   PubMed Web of Science ®Google Scholar
• DI BIASE AM, PIETRANTONI A, TINARI A et al.: Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. Med. Virol (2003) 69:495–502.
   PubMed Web of Science ®Google Scholar
• Y00 Y-C, WATANABE R, KOIKE Y et al.: Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of the reactive oxygen species. Biochem. Biophys. Res. Commun. (1997) 237:624–628.
   Google Scholar
• YANG N, STENSEN W, SVENDSEN JS, REKDAL 0: Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. Peptide Res. (2002) 60:187–197.
   Google Scholar
• ELIASSEN LT, BERGE G, SVEINBJORNSSON B, SVENDSEN JS, VORLAND LH, REKDAL 0: Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anti Cancer Res. (2002) 22:2703–2710.
   PubMed Web of Science ®Google Scholar
• KUHARA T, IIGO M, USHIDA Y et al.:Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer (2000) 38:192–199.
   PubMed Web of Science ®Google Scholar
• SHARMA S, KUMAR P, BETZEL C, SINGH TP: Structure and function of proteins involved in milk allergies. .1. Chromatog. B (2001) 756:183–187.
   PubMed Web of Science ®Google Scholar
• MURATORI L, MURATORI P, ZAULI D et al.: Antilactoferrin antibodies in autoimmune liver disease. Clin. Exp. Immunol (2001) 124:470–474.
   PubMed Web of Science ®Google Scholar
• THOMAS LL, XU W, ARDON TT: Immobilized lactoferrin is a stimulus for eosinophil activation. Immunol (2002) 169:993–999.
   Web of Science ®Google Scholar
• WEINBERG ED: Iron-enriched rice: the case for labeling. Med. Food (2000) 3:189–191.
   PubMedGoogle Scholar
• BYRD TF, HORWITZ MA: Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and interferon gamma-activated human momocytes depending upon its degree of iron saturation. Clin. Invest. (1991) 88:1103–1112.
   Google Scholar
• SCHRYVERS AB, BONNAH R, YU R-H, WONG H, RETZER M: Bacterial lactoferrin receptors. Adv. Exp. Med. (1998) 443:123–133.
   PubMed Web of Science ®Google Scholar
• WILSON ME, LEWIS TS, MILLER MA, MCCORMICK ML, BRITIGAN BE: Leishmania chagasli uptake of iron bound to lactoferrin or transferring requires an iron reductase. Exp. Parasitol (2002) 100:196–207.
   PubMed Web of Science ®Google Scholar
• GUTTNER Y, WINDSOR HM, VIIALA CH, MARSHALL BJ: Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment. Pharmacol Ther. (2003) 17:125–129.
   PubMed Web of Science ®Google Scholar
• DHAENENS L, SZCZEBARA F, HUSSON MO: Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect. Immun. (1997) 65:514–518.
   PubMed Web of Science ®Google Scholar
• •An important potential hazard re-use of hLf.
   Google Scholar
• MIEHLKE S, REDDY R, OSATO MS, WARD PP, CONNEELY OM, GRAHAM DY: Direct activity of recombinant human lactoferrin against HelicobacterClin. Microbial (1996) 34:2593–2594.
   Web of Science ®Google Scholar
• OPEKUN AR, EL-ZAIMAITY HMT, OSATO MS et al.: Novel therapies for Helicobacter pylori. Aliment. Pharmacol The]: (1999) 13:35–41.
   PubMed Web of Science ®Google Scholar
• MORIUCHI M, MORIUCHI H: A milk protein lactoferrin enhances human T cell leukemia virus Type 1 and suppresses FM/-1 infection.j Immunol (2001)166:4231–4236.
   PubMed Web of Science ®Google Scholar
• BROCK JH: The physiology of lactoferrin. Biochem. Cell Biol. (2002) 80:1–6.
   PubMed Web of Science ®Google Scholar
• •A useful recent review of basic aspects of Lf.
   Google Scholar
• DEFER MC, DUGAS B, PICARD 0, DAMAIS C: Impairment of circulating lactoferrin in HIV-1 infection. Cell. MM. Biol. (1995) 41:417–421.
   PubMed Web of Science ®Google Scholar
• BELJAARS L, BAKER HI, VAN DER STRATE BWA et al.: The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues. Pharm. Res. (2002) 19:54–62.
   Google Scholar
• VAN HOOIJDONK ACM, KUSSENDRAGER KD, STEIJNE JM: In vivo antimicrobial and antiviral activity of components in bovine milk and colostrums involved in non-specific defence. Br.Nutr. (2000) 84\(Suppl. 1):5127–5134.
   Google Scholar